Skip to main content
. 2022 Apr 19;12(4):e053964. doi: 10.1136/bmjopen-2021-053964

Figure 1.

Figure 1

Percentage of patients with exacerbations according to their severity. Values expressed as a percentage of patients with exacerbations during the follow-up year. In grey: statistically significant results (p<0.05). Groups: fluticasone propionate/salmeterol (FP/SAL), beclomethasone/formoterol (BDP/FORM), budesonide/formoterol (BUD/FORM), fluticasone furoate/vilanterol (FF/VI) and fluticasone propionate/formoterol (FP/FORM).